Increased cardio risk of Saxagliptin found during trial prompts FDA decision.

Trial results promising, but DKA still a concern with use of new once-daily pills.

Philadelphia youth see rise in diagnosis; especially for African Americans, by 70%.

Common osteoarthritis treatment may be beneficial in lowering HbA1c.

By Featured Writer Sheri R. Colberg, PhD. As a clinical exercise researcher, I frequently have found it difficult to study exercise effects in people with health complications, even though this is critical information to know in order to make appropriate exercise guidelines. Try convincing your university Institutional Research Board, or IRB, that it is advisable to exercise people with eye issues like unstable proliferative retinopathy to find out if breath-holding, jumping, jarring, or head-down activities cause them to experience retinal hemorrhages. Understandably, that is not going to happen, nor should it.

One of your patients is currently taking metformin, glyburide, and an evening basal dose of insulin. After discussing how best to achieve better glycemic control, he has agreed to add a pre-meal insulin dose. Which modification should be made with the addition of the prandial dose? A. Discontinue the glyburide B. Discontinue the metformin C. No modifications should be made D. Discontinue the metformin, glyburide, and evening insulin Follow the link for the correct answer.

For a 2nd add-on drug to prescribe to those with type 2 diabetes and who are not meeting either an A1c goal of 6% or less, or an A1c of 7.5% with no complications, which might you prefer to add on to metformin to reach the goal of 6%? 1. DPP-4 Inhibitor 2. SGLT-2 Inhibitor 3. TZD 4. Sulfonylurea 5. Dopamine receptor agonist 6. GLP-1 Agonists Follow the link to share your response.

By: Medtroninc, Inc. Price: Free Description: This on-the-go support tool is perfect for anyone who uses a Medtronic insulin pump and continuous glucose monitor. With myMedtronic Connect, you can order supplies and accessories, access helpful tips and explanations, set reminders, and prepare for travel. Details: Medtronic, Inc. Released: August 2, …

Dr. Mark Molitch is the Martha Leland Sherwin Professor of Medicine at Northwestern in the Division of Endocrinology, Metabolism and Molecular Medicine. Dr. Molitch has been active in clinical research in diabetes, focusing on diabetic nephropathy, and other areas of endocrinology.

In this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about how doctors can educate patients on nutrition and diet issues, the advances in diabetes technology, and the complexities of diabetes multi-drug therapies.